BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer.

ABSTRACT:

Background

Mutations of v-raf murine sarcoma viral oncogene homolog B (BRAF) are commonly identified in papillary and anaplastic thyroid carcinoma and are associated with worse prognosis compared with the wild type. BRAF inhibition in papillary thyroid carcinoma cell lines and xenografts inhibits proliferation and decreases downstream phosphorylation. Our objectives were to analyze safety and efficacy of the selective BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid carcinoma.

Methods

We present the subset of patients with BRAF-mutant thyroid carcinoma enrolled in a larger phase 1 study, the main results of which are reported elsewhere.

Results

Fourteen patients with BRAF(V600E)-mutant thyroid carcinoma were enrolled, of whom 13 (93%) had rece

SUBMITTER: Falchook GS 

PROVIDER: S-EPMC4291160 | biostudies-literature | 2015 Jan

REPOSITORIES: biostudies-literature